Radiotherapy and targeted therapy for cervical cancer are two completely different treatments, with different treatment methods and therapeutic purposes, and generally there is no saying which one is better.
Radiotherapy includes extracorporeal irradiation, brachytherapy and combined application of both. Preoperative radiotherapy can reduce tumor activity, narrow the scope of tumor and increase the rate of surgical resection; postoperative radiotherapy can assist in the treatment of cervical cancer with poor prognosis, and the poor prognostic factors include lymph node metastasis, positive margins, paracervical infiltration, deep infiltration, and cholangiocarcinoma embolus.
Targeted therapy is to select targeted drugs for different pathogenic mechanisms. At present, the therapeutic “targets” of cervical cancer have been widely researched, such as anti-angiogenic drugs can promote apoptosis of tumor cells, and the combination of monoclonal antibody against EGFR and cisplatin can reduce the tolerance of tumors.
The combination of monoclonal antibody to EGFR and cisplatin can reduce tumor tolerance. mTOR inhibitors can improve the therapeutic efficacy of human papillomavirus (HPV)-associated cervical cancer, and the combination of paclitaxel, cisplatin, and veraparib can enhance the safety of cervical cancer treatment by targeting the DNA damage repair pathway, and so on.
If cervical cancer exists in patients, it is recommended to go to regular hospitals in time, complete relevant examinations, clarify the cause of the disease under the guidance of doctors, and formulate targeted treatment plans to avoid delaying the condition. The use of the above medications should be in accordance with medical advice.